GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hugel Inc (XKRX:145020) » Definitions » Current Deferred Revenue

Hugel (XKRX:145020) Current Deferred Revenue : ₩0 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Hugel Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Hugel's current deferred revenue for the quarter that ended in Mar. 2024 was ₩0 Mil.

Hugel Current Deferred Revenue Historical Data

The historical data trend for Hugel's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hugel Current Deferred Revenue Chart

Hugel Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hugel Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Hugel Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Hugel's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hugel (XKRX:145020) Business Description

Traded in Other Exchanges
N/A
Address
61-20, Sinbuk-ro, Sinbuk-eup, Chuncheon, Gangwon, KOR, 24206
Hugel Inc is a biopharmaceutical company. It is in the business of manufacturing of biopharmaceuticals. The company's primary products are Botulinum toxin, Hyaluronic acid filler, and Cosmetics. It develops and promotes its products under the brand name of Wellage. The firm has manufacturing facilities in Shinbuk and Geodu.

Hugel (XKRX:145020) Headlines

No Headlines